Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$106.12 USD

106.12
253,687

-1.97 (-1.82%)

Updated Jul 30, 2024 03:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain LHC Group (LHCG) Stock Now

by Zacks Equity Research

LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.

Here's Why You Should Hold on to DaVita (DVA) Stock For Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

PerkinElmer's (PKI) Arm Introduces Two CE-Marked Assays

by Zacks Equity Research

PerkinElmer's (PKI) company launches two CE-marked antibody tests that can support the analysis of the immune response to COVID-19.

Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

West Pharmaceutical's (WST) Syringe System to Improve Outcome

by Zacks Equity Research

West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

What's in Store for Patterson Companies' (PDCO) Q4 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.

BD's (BDX) Latest Collaboration to Enhance Patient Care

by Zacks Equity Research

BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.

Here's Why You Should Hold on to Ecolab (ECL) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

CONMED (CNMD) to Expand Orthopedic Portfolio With Buyout

by Zacks Equity Research

CONMED's (CNMD) completion of In2Bones Global buyout will expand its orthopedic portfolio.

Here's Why You Should Hold on to Accuray (ARAY) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.

Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine

by Zacks Equity Research

Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.

BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox

by Zacks Equity Research

BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.

Veeva Systems (VEEV) Unveils New Study Training Application

by Zacks Equity Research

Veeva Systems' (VEEV) new clinical study training application will address the demands and complexities involved in present-day trials.

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

PerkinElmer (PKI) Unveils New NGS System to Aid Genomic Analysis

by Zacks Equity Research

PerkinElmer's (PKI) introduction of the RUO BioQule NGS System is a cost-effective system that can bring improvements in genomic analysis.

BD (BDX) to Expand Base in Pharmacy Automation With New Buyout

by Zacks Equity Research

BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.

Here's Why You Should Hold on to Avanos (AVNS) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.